The Precision Peptide Company Applauds FDA Action Advancing Regulatory Clarity for Peptide Therapies

Vancouver, British Columbia--(Newsfile Corp. - April 16, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a company focused on the next-generation of peptide-based products and delivery systems, commends the U.S. Food and Drug Administration (FDA) for its recent actions to advance regulatory clarity surrounding peptide substances. The FDA's decision to remove several peptides from Category 2 of bulk drug substances and refer them to further evaluation by the Pharmacy Compounding Advisory Committee (PCAC) marks a meaningful step toward establishing a more transparent and science-driven regulatory framework.